Q-omics provides the consensus-scored MIR3976HG profile across patient tissues and cancer cell-line models. MIR3976HG expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR3976HG is differentially expressed in 1, with the highest sampling consensus in UCEC. Additionally, MIR3976HG RNA expression shows 6,571 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, UCEC, and STAD as cancer lineages where MIR3976HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3976HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3976HG survival associations across molecular data types. MIR3976HG RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3976HG RNA expression–survival associations across cancer types. High MIR3976HG expression shows unfavorable associations in UCS, KIRP, CESC, KIRC and THYM, but favorable associations in PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR3976HG RNA expression.
This table summarizes MIR3976HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3976HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3976HG shows higher tumor expression in UCEC. The UCEC box plot shows higher MIR3976HG RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .035).
This table shows molecular features associated with MIR3976HG in patient tissues and cancer cell lines. In patient samples, MIR3976HG shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
